The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 01, 2020
Filed:
Nov. 06, 2018
Applicant:
Tiziana Life Sciences Plc, London, GB;
Inventor:
Kunwar Shailubhai, Line Lexington, PA (US);
Assignee:
Tiziana Life Sciences PLC, London, GB;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/4412 (2006.01); A61K 31/47 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01); A61K 31/404 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/0053 (2013.01); A61K 31/404 (2013.01); A61K 31/4412 (2013.01); A61K 31/47 (2013.01); A61P 35/00 (2018.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 2300/00 (2013.01);
Abstract
This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).